Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD1-PSMA-CART in CRPC
NCT04768608Phase 1Completed
- Sponsor
- Zhejiang University
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PD1-PSMA-CART in castration-resistant prostate cancer (CRPC), sponsored by Zhejiang University. Primary endpoint: Incidence of toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events at 28 days. Started Dec 2021; status: completed.
02
Drugs
PD1-PSMA-CART
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04768608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04768608.